Welcome to Chinese Journal of Clinical Pharmacology and Therapeutics,Today is Chinese

Chinese Journal of Clinical Pharmacology and Therapeutics ›› 1999, Vol. 4 ›› Issue (2): 112-114.

Previous Articles     Next Articles

Relative bioavailability and bioequivalence evaluation of gliclazide tablets

XU Rong-Qing, DENG Shi-Shan, XIA Zhi-Lin, GUO Shun-Min   

  1. Department of Pharmaceutics, Fujian Medical Science Institute, Fuzhou 350001
  • Received:1999-04-22 Revised:1999-05-10 Online:1999-06-26 Published:2020-12-04

Abstract: Aim To compare relative bioavailability and bioequivalence of gliclazide tablets. Methods Ten healthy male volunteers in two groups were given orally gliclazide tested and reference tablets (160 mg)in randomized crossover study.The serum concentration of gliclazide was assayed by HPLC and the bioequivelence of two formulations was evaluated by analysis of two onesided tests.Results Serum concentration-time curves of gliclazide fitted to an one-compartment open model.Tmax were (4.272±0.631)h and (4.031±0.574)h, Cmax were (7.497±0.935)μg·ml-1 and (7.408±1.171)μg·ml-1 and AUC were (104.986±27.523)μg·h·ml-1 and (108.232±22.437) μg·h·ml-1 for tested and reference tablets, respectively.The relative bioavailability of gliclazide tested tablet was 96.679%. Conclusion The tested and reference tablets of gliclazide are of bioequivalence.

Key words: gliclazide, bioavailability, bioequivalence

CLC Number: